Navigation Links
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Date:10/12/2008

Quark siRNAs Examined Alone and in Combination with Chemotherapy

FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008. The paper, entitled "RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy," reports on research performed in collaboration with Professor Shyam Biswal of the Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University. The results provide a basis for a potential new drug candidate to be added to Quark's pipeline.

The study examined efficacy of RNAi-mediated reduction of Nuclear Factor Erythroid-2-Related Factor 2 (Nrf2) expression in vitro and in in vivo mouse NSCLC xenograft models alone or in combination with chemotherapy. The results show that RNAi-mediated reduction of Nrf2 expression generates reactive oxygen species, suppresses tumor growth, and increases sensitivity to chemotherapeutic drug-induced cell death.

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer of Quark Pharmaceuticals, said, "Nrf2 appears in our IP portfolio as a novel drug target for cancer treatment. Discovery of the target's role in cancer was made years ago, using our proprietary functional high throughput drug target discovery method, BiFAR(TM), when we looked for genes whose inhibition could sensitize cancer cells to apoptosis. Since then, much progress has been made to study the concept of Nrf2 inhibition for cancer treatment by the scientific community. One of the major contributors in this field is Prof. Biswal from Johns Hopkins University wi
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014   OTEMR, Inc. ... Edition Complete EHR certification, which designates that the software ... Stage 1 and Stage 2 Meaningful Use measures required ... Reinvestment Act (ARRA).  ONETOUCH EMR 2.0 was certified on ... Office of the National Coordinator-Authorized Certification Body (ONC-ACB) and ...
(Date:9/17/2014)... MUMBAI, India , September 17, 2014 ... TRPA1 antagonist, GRC 17536, has shown positive data in ... with painful diabetic neuropathy , ... Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 ... blind, placebo controlled, multi-centre, proof of concept study conducted ...
(Date:9/17/2014)... 17, 2014  Bayer HealthCare will present data on ... th Annual Meeting, which takes place September 18-20 ... which will be shared through poster presentations, showcase Bayer,s ... Data will be presented in a scientific forum. ... in hemophilia A patients, Bayer is maintaining its commitment ...
Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4
... and SAN FRANCISCO , May 31 Dendreon Corporation ... the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an ... of the American Urological Association (AUA) in San Francisco . ... "The approval of PROVENGE ...
... , May 28, 2010 Shire plc (LSE: SHP,NASDAQ: ... Paragraph IV Notice Letter today from Zydus,Pharmaceuticals USA, Inc. ("Zydus") advising of ... of Shire,s 1.2g,mesalamine delayed release tablets, LIALDA(R). , ... LIALDA is protected by the ...
Cached Medicine Technology:Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting 2Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting 3Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting 4Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals 2Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals 3
(Date:9/17/2014)... September 17, 2014 The global metrology ... worth due to the key driving factors of increasing ... expected CAGR of 8.2 % puts the metrology services ... in 2018, as stated in a Transparency Market Research ... Size, Share, Growth, Trends, and Forecast 2012 – 2018”. ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 For over ... supplier of MadgeTech data logging products to industries in ... equipment and the development of management systems for certification ... service, quality, and technical support. , MadgeTech Inc. ... reach internationally. “We are very pleased to see the ...
(Date:9/17/2014)... NY (PRWEB) September 17, 2014 ... and Access Management (IdM/IAM) solutions and Boston ... announced their business partner relationship. Under ... Systems’ technology to automate functionality within its ... Boston Software Systems provides healthcare automation platforms ...
(Date:9/17/2014)... NJ (PRWEB) September 17, 2014 ... Application Security Testing (SAST) tool, at AppSec USA 2014 ... from 9 am to 6 pm at booth G4 ... one of the leading software security conferences for developers, ... a tool that provides developers and managers with the ...
(Date:9/17/2014)... release is available in Spanish . ... more than half of the population in our Community. ... of which affects liver function. Fat accumulates in the ... inflammation, fibrosis and finally, cirrhosis. To date, the most ... biopsy. Imaging techniques such as abdominal ecography detect it ...
Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Main Solutions Now Distributing MadgeTech Data Loggers in Bulgaria 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:Magnetic resonance helps to detect and quantify fat in liver 2
... it has been known that aspirin is beneficial to ... of the many different types of aspirin is likely ... led by Dr. Sean Nordt from the University of ... to a group of volunteer research subjects: regular aspirin ...
... May 15 Endocare, Inc. (Nasdaq: ENDO ... development of minimally invasive technologies used by urologists and ... results for the first quarter ended March 31, 2009. ... increase in revenue and strong margins.Total revenues for the ...
... Dr. Bruno E. Gerber is recognized in ... is a Consultant Orthopedic Surgeon with a special ... of the lower limbs. He also is employed ... development project regarding innovative orthopedic laser treatment.Dr. Gerber ...
... in Steinbach, Manitoba , ... Steinbach, Manitoba, Canada (Vocus) May 15, 2009 ... chronic pain. Even pop singer, famed choreographer, and American Idol judge, Paula ... the May issue of Ladies Home Journal. While Abdul admits to being ...
... influenza epidemic has raised many questions about how animal ... through veterinarians, who, according to a new report by ... at markedly increased risk of infection with zoonotic pathogens ... animals and humans. , While there is no ...
... Hundreds of Albert Lea residents joined together on Thursday ... the AARP(R)/Blue Zones(R) Vitality Project sponsored by United Health ... residents to take charge of their health so that ... leaders have been working behind the scenes with the ...
Cached Medicine News:Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional 2Health News:Chronic Pain Sufferers Find Hope in the Darkness 2Health News:Veterinarians at high risk for viral, bacterial infections from animals 2Health News:Veterinarians at high risk for viral, bacterial infections from animals 3Health News:Albert Lea Residents Pledge to Add 10,000 Collective Years of Life to Their City 2Health News:Albert Lea Residents Pledge to Add 10,000 Collective Years of Life to Their City 3Health News:Albert Lea Residents Pledge to Add 10,000 Collective Years of Life to Their City 4Health News:Albert Lea Residents Pledge to Add 10,000 Collective Years of Life to Their City 5
Agility has delivered a RFID-enabled mobile asset management program....
... VerdaSee Location-ID™ is a family of ... equipment and individuals inside hospitals, healthcare ... frequency technology. The target tracking areas ... a series of radio frequency identification ...
The WatchMate LC model is a cost-effective solution for monitoring a single exit, and provides local notification of an alarm....
Assetrac allows identification, location, and protection of your assets....
Medicine Products: